Equillium, a biotechnology company, failed to acquire Metacrine, a clinical-stage bio pharmaceutical company, for $33m. On December 23, 2022, Metacrine and Equillium announced the mutual termination of their previously announced definitive merger agreement. Metacrine is continuing to evaluate all strategic opportunities.